Angela B. Mariotto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Angela B. Mariotto has a total of 179 co-authors. Here are the top co-authors by number of shared publications:
- Theresa P. Devasia
National Cancer Institute 1 Division of Cancer Control and Population Sciences Bethesda, Maryland
119 shared publications - Ruth Etzioni
Fred Hutch Cancer Center, Seattle, WA
59 shared publications - Yaw A. Nyame
Department of Urology, University of Washington, Seattle, Washington
58 shared publications - Nadia Howlader
Surveillance Research Program Division of Cancer Control and Population Sciences National Cancer Institute Bethesda Maryland USA
46 shared publications - Jennifer L. Stevens
Information Management Services, Inc , Calverton, MD
28 shared publications - Karen Mittu
Information Management Services Calverton Maryland USA
27 shared publications
Latest Publications
- 26 September 2026
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 118 (11) , 2219-2220
Response to Wu, Lu, and Yang
- 26 September 2026
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 118 (11) , 2219-2220
Response to Wu, Lu, and Yang
- 28 July 2026
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 118 (11) , 2145-2158
Cancer-attributable costs in older adults: SEER-Medicare analysis of variation by site, stage, and race
Background: Advances in cancer treatment and increased survivorship have altered the economic burden of cancer care. Updated patient-level estimates of cancer-attributable costs, based on clinical and socioeconomic factors, are required. Methods: Using the Surveillance, Epidemiology, and End Results (SEER)-Medicare linked data, we identified individuals aged ≥66 years who were diagnosed with cancer during 2008-2019 and matched controls without a cancer history based on demographic characteristics, comorbidity burden, and area-level socioeconomic status. Cancer-attributable costs were estimated for 2013-2019 according to cancer site, stage, age, sex, race, and calendar year. Phases of care were defined as initial (first 12 months after diagnosis), continuing, and end-of-life (EOL; final 12 months before death from cancer). Net annualized cancer-attributable costs were calculated as the difference between cases and matched controls and are reported in USD 2023. Results: Net annualized cancer-attributable medical service costs were highest in the EOL phase ($121 746), followed by the initial ($45 063), and continuing ($7141) phases. Oral prescription drug costs increased over time across all phases, particularly in EOL (from $4823 in 2013 to $11 620 in 2019), whereas medical service and hospitalization costs remained relatively stable after adjustment for inflation. Acute leukemia and distant-stage cancers incurred the highest cost. Cancer-attributable costs were higher among Black individuals and individuals of other races than among White individuals. Conclusion(s): Cancer-attributable costs vary substantially according to the care phase, cancer type, stage at diagnosis, and race. Rising costs, particularly for EOL care and prescription drugs, highlight the importance of aligning treatment intensity with patient goals and providing critical inputs for simulation and cost-effectiveness analyses of cancer-control interventions.
- 28 July 2026
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 118 (11) , 2145-2158
Cancer-attributable costs in older adults: SEER-Medicare analysis of variation by site, stage, and race
Background: Advances in cancer treatment and increased survivorship have altered the economic burden of cancer care. Updated patient-level estimates of cancer-attributable costs, based on clinical and socioeconomic factors, are required. Methods: Using the Surveillance, Epidemiology, and End Results (SEER)-Medicare linked data, we identified individuals aged ≥66 years who were diagnosed with cancer during 2008-2019 and matched controls without a cancer history based on demographic characteristics, comorbidity burden, and area-level socioeconomic status. Cancer-attributable costs were estimated for 2013-2019 according to cancer site, stage, age, sex, race, and calendar year. Phases of care were defined as initial (first 12 months after diagnosis), continuing, and end-of-life (EOL; final 12 months before death from cancer). Net annualized cancer-attributable costs were calculated as the difference between cases and matched controls and are reported in USD 2023. Results: Net annualized cancer-attributable medical service costs were highest in the EOL phase ($121 746), followed by the initial ($45 063), and continuing ($7141) phases. Oral prescription drug costs increased over time across all phases, particularly in EOL (from $4823 in 2013 to $11 620 in 2019), whereas medical service and hospitalization costs remained relatively stable after adjustment for inflation. Acute leukemia and distant-stage cancers incurred the highest cost. Cancer-attributable costs were higher among Black individuals and individuals of other races than among White individuals. Conclusion(s): Cancer-attributable costs vary substantially according to the care phase, cancer type, stage at diagnosis, and race. Rising costs, particularly for EOL care and prescription drugs, highlight the importance of aligning treatment intensity with patient goals and providing critical inputs for simulation and cost-effectiveness analyses of cancer-control interventions.
- 21 July 2026
- Published by Wolters Kluwer Health in Medical Care
- Vol. 64 (11) , 787-792
Receipt of Cancer Surgery
Background: The Surveillance, Epidemiology, and End Results (SEER) Program collects data on cancer incidence and treatments given as the first course of therapy. Medicare claims are another source of cancer treatment-related information. We assessed the agreement between these data sources to identify cancer surgery. Methods: We used the SEER-Medicare data to create a female breast and bladder cancer cohort that included patients diagnosed from 2004 to 2019 and continuously enrolled in Parts A/B fee-for-service from 4 months before at least 12 months following diagnosis, the window for surgery assessment. The presence/absence of Medicare surgery treatment claims was compared with SEER surgery data. Results: Of the 146,180 patients with breast cancer, 90.3% had surgery, and 6.4% did not have surgery per both SEER and Medicare. Surgery was identified in SEER only for 1.3% and in Medicare only for 1.6% (exact agreement=97%, κ=0.80). In the bladder cancer cohort (n=47,882), 90.9% had surgery and 1.8% did not, per both SEER and Medicare data. Surgery was recorded in SEER only for 2.2% and in Medicare only for 4.6% (exact agreement=93%, κ=0.31). For 0.1% of breast cancer patients and 0.3% of bladder cancer patients, surgery status was unknown per SEER, but Medicare surgery claims were present. Conclusions: Overall, there was high agreement between SEER and Medicare claims in identifying breast and bladder cancer surgery, but there were some patients who received bladder cancer surgery per Medicare but not per SEER. It is possible that patients received surgeries in the community setting, which were not reported to SEER.
- 21 July 2026
- Published by Wolters Kluwer Health in Medical Care
- Vol. 64 (11) , 787-792
Receipt of Cancer Surgery
Background: The Surveillance, Epidemiology, and End Results (SEER) Program collects data on cancer incidence and treatments given as the first course of therapy. Medicare claims are another source of cancer treatment-related information. We assessed the agreement between these data sources to identify cancer surgery. Methods: We used the SEER-Medicare data to create a female breast and bladder cancer cohort that included patients diagnosed from 2004 to 2019 and continuously enrolled in Parts A/B fee-for-service from 4 months before at least 12 months following diagnosis, the window for surgery assessment. The presence/absence of Medicare surgery treatment claims was compared with SEER surgery data. Results: Of the 146,180 patients with breast cancer, 90.3% had surgery, and 6.4% did not have surgery per both SEER and Medicare. Surgery was identified in SEER only for 1.3% and in Medicare only for 1.6% (exact agreement=97%, κ=0.80). In the bladder cancer cohort (n=47,882), 90.9% had surgery and 1.8% did not, per both SEER and Medicare data. Surgery was recorded in SEER only for 2.2% and in Medicare only for 4.6% (exact agreement=93%, κ=0.31). For 0.1% of breast cancer patients and 0.3% of bladder cancer patients, surgery status was unknown per SEER, but Medicare surgery claims were present. Conclusions: Overall, there was high agreement between SEER and Medicare claims in identifying breast and bladder cancer surgery, but there were some patients who received bladder cancer surgery per Medicare but not per SEER. It is possible that patients received surgeries in the community setting, which were not reported to SEER.
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from Trends in Long-Term Excess Mortality Risk and Survival among Childhood and Adolescent Cancer Survivors in the United States
Standardized mortality ratios (SMRs) and absolute risk of all-cause mortality among children and adolescents diagnosed with neuroblastoma and Wilms tumor, SEER 8, 1975-2021.
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from Trends in Long-Term Excess Mortality Risk and Survival among Childhood and Adolescent Cancer Survivors in the United States
Standardized mortality ratios (SMRs) and absolute risk of all-cause mortality among children and adolescents diagnosed with neuroblastoma and Wilms tumor, SEER 8, 1975-2021.
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Assessing Trends in Conditional Survival for Non–Hodgkin Lymphoma and Chronic Myeloid Leukemia via Novel Extensions to the Joinpoint Survival Model
This table displays the conditional JPSurv simulation results under each scenario.
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Assessing Trends in Conditional Survival for Non–Hodgkin Lymphoma and Chronic Myeloid Leukemia via Novel Extensions to the Joinpoint Survival Model
This table displays the conditional JPSurv simulation results under each scenario.
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Assessing Trends in Conditional Survival for Non–Hodgkin Lymphoma and Chronic Myeloid Leukemia via Novel Extensions to the Joinpoint Survival Model
This table outlines the settings used in the simulation study comparing the two methods of examining conditional survival trends.
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Assessing Trends in Conditional Survival for Non–Hodgkin Lymphoma and Chronic Myeloid Leukemia via Novel Extensions to the Joinpoint Survival Model
This table outlines the settings used in the simulation study comparing the two methods of examining conditional survival trends.
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Assessing Trends in Conditional Survival for Non–Hodgkin Lymphoma and Chronic Myeloid Leukemia via Novel Extensions to the Joinpoint Survival Model
This figures compares Landmarked JPSurv model predictions to predictions from the JPSurv post-calculation method.
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Assessing Trends in Conditional Survival for Non–Hodgkin Lymphoma and Chronic Myeloid Leukemia via Novel Extensions to the Joinpoint Survival Model
This figures compares Landmarked JPSurv model predictions to predictions from the JPSurv post-calculation method.
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Assessing Trends in Conditional Survival for Non–Hodgkin Lymphoma and Chronic Myeloid Leukemia via Novel Extensions to the Joinpoint Survival Model
This file displays trends in 1-year and 5-year relative survival.
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Assessing Trends in Conditional Survival for Non–Hodgkin Lymphoma and Chronic Myeloid Leukemia via Novel Extensions to the Joinpoint Survival Model
This file displays trends in 1-year and 5-year relative survival.
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Data from Assessing Trends in Conditional Survival for Non–Hodgkin Lymphoma and Chronic Myeloid Leukemia via Novel Extensions to the Joinpoint Survival Model
Background:Five-year relative survival for non–Hodgkin lymphoma (NHL) and chronic myeloid leukemia (CML) has improved, reflecting therapeutic advances, but prognosis beyond 5 years after diagnosis is less understood. We introduced a method to estimate trends in conditional survival, the probability of further survival given survival to a specific time.Methods:We developed a landmarked joinpoint survival (JPSurv) model that uses data beginning at a prespecified follow-up interval. We apply this approach to NHL (overall and by major subtype) and CML survival data from the Surveillance, Epidemiology, and End Results program. We estimated calendar trends in both 5-year relative survival and 5-year conditional relative survival (given survival to 5 years) using annual absolute changes in survival represented by percentage points (pp) over a time frame.Results:The largest annual increases in 5-year relative survival were observed for diffuse large B-cell lymphoma (+2.44 pp 1995–2002) and CML (+2.52 pp 1996–2011). Five-year conditional relative survival improved most for CML (+1.79 pp 1985–2016), chronic lymphocytic leukemia/small lymphocytic lymphoma (+0.80 pp 1988–2016), and follicular lymphoma (+80 pp 1990–2016). For patients diagnosed after 2010, 5-year conditional relative survival was approximately 90% for all cancers studied.Conclusions:Both 5-year relative survival and 5-year conditional relative survival improved substantially, reflecting advances in therapy and long-term patient outcomes.Impact:The landmarked JPSurv model is a novel framework for conditional survival analysis that can be used to inform survivorship research, offering insight into lasting treatment effects and the likelihood of patients obtaining a sustained remission.
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Assessing Trends in Conditional Survival for Non–Hodgkin Lymphoma and Chronic Myeloid Leukemia via Novel Extensions to the Joinpoint Survival Model
Background:Five-year relative survival for non–Hodgkin lymphoma (NHL) and chronic myeloid leukemia (CML) has improved, reflecting therapeutic advances, but prognosis beyond 5 years after diagnosis is less understood. We introduced a method to estimate trends in conditional survival, the probability of further survival given survival to a specific time.Methods:We developed a landmarked joinpoint survival (JPSurv) model that uses data beginning at a prespecified follow-up interval. We apply this approach to NHL (overall and by major subtype) and CML survival data from the Surveillance, Epidemiology, and End Results program. We estimated calendar trends in both 5-year relative survival and 5-year conditional relative survival (given survival to 5 years) using annual absolute changes in survival represented by percentage points (pp) over a time frame.Results:The largest annual increases in 5-year relative survival were observed for diffuse large B-cell lymphoma (+2.44 pp 1995–2002) and CML (+2.52 pp 1996–2011). Five-year conditional relative survival improved most for CML (+1.79 pp 1985–2016), chronic lymphocytic leukemia/small lymphocytic lymphoma (+0.80 pp 1988–2016), and follicular lymphoma (+80 pp 1990–2016). For patients diagnosed after 2010, 5-year conditional relative survival was approximately 90% for all cancers studied.Conclusions:Both 5-year relative survival and 5-year conditional relative survival improved substantially, reflecting advances in therapy and long-term patient outcomes.Impact:The landmarked JPSurv model is a novel framework for conditional survival analysis that can be used to inform survivorship research, offering insight into lasting treatment effects and the likelihood of patients obtaining a sustained remission.
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Assessing Trends in Conditional Survival for Non–Hodgkin Lymphoma and Chronic Myeloid Leukemia via Novel Extensions to the Joinpoint Survival Model
This figures compares the unconditional and conditional survival trends when considering short term (i.e. 1 year past the 5-year survival mark) conditional survival.
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Assessing Trends in Conditional Survival for Non–Hodgkin Lymphoma and Chronic Myeloid Leukemia via Novel Extensions to the Joinpoint Survival Model
This figures compares the unconditional and conditional survival trends when considering short term (i.e. 1 year past the 5-year survival mark) conditional survival.